Allergy Therapeutics (AGY) Competitors GBX 8.18 +0.18 (+2.25%) As of 06:53 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock AGY vs. AMYT, APH, ANCR, STX, VLG, EAH, DNL, PXS, MXC, and RGTShould you be buying Allergy Therapeutics stock or one of its competitors? The main competitors of Allergy Therapeutics include Amryt Pharma (AMYT), Alliance Pharma (APH), Animalcare Group (ANCR), Shield Therapeutics (STX), Venture Life Group (VLG), ECO Animal Health Group (EAH), Diurnal Group (DNL), Provexis (PXS), Argent BioPharma (MXC), and Argent BioPharma (RGT). These companies are all part of the "drug manufacturers - specialty & generic" industry. Allergy Therapeutics vs. Its Competitors Amryt Pharma Alliance Pharma Animalcare Group Shield Therapeutics Venture Life Group ECO Animal Health Group Diurnal Group Provexis Argent BioPharma Argent BioPharma Amryt Pharma (LON:AMYT) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation. Is AMYT or AGY more profitable? Amryt Pharma has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -72.86%. Amryt Pharma's return on equity of 0.00% beat Allergy Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amryt PharmaN/A N/A N/A Allergy Therapeutics -72.86%-266.59%-34.76% Does the media favor AMYT or AGY? In the previous week, Amryt Pharma's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score. Company Overall Sentiment Amryt Pharma Neutral Allergy Therapeutics Neutral Which has stronger valuation and earnings, AMYT or AGY? Amryt Pharma has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmryt Pharma£210.24M0.00N/A-£33.00N/AAllergy Therapeutics£72.18M5.57-£52.59M-£1.04-7.88 SummaryAmryt Pharma beats Allergy Therapeutics on 5 of the 6 factors compared between the two stocks. Get Allergy Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGY vs. The Competition Export to ExcelMetricAllergy TherapeuticsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£402.05M£2.18B£5.75B£3.17BDividend Yield8.33%2.92%3.95%5.04%P/E Ratio-7.884.3531.31169.05Price / Sales5.57651.74439.11464,526.94Price / Cash3.6610.3737.7327.93Price / Book82.8911.2810.536.83Net Income-£52.59M£20.70B£3.27B£5.89B7 Day Performance-5.98%0.98%1.35%0.15%1 Month Performance-0.24%5.21%6.13%49.89%1 Year Performance97.58%5.26%49.95%152.06% Allergy Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGYAllergy TherapeuticsN/AGBX 8.18+2.3%N/A+81.3%£402.05M£72.18M-7.88612Gap UpAMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAPHAlliance Pharma1.8765 of 5 starsGBX 64.70flatGBX 6,250+9,560.0%N/A£350.32M£183.50M-10.4391,000ANCRAnimalcare GroupN/AGBX 259+2.8%N/A-4.7%£177.57M£84.90M4.83220Gap UpSTXShield TherapeuticsN/AGBX 7.71+7.8%N/A+75.2%£76.09M£20.92M-1.9940,000Gap UpHigh Trading VolumeVLGVenture Life GroupN/AGBX 57.95-0.1%N/A+21.3%£73.84M£51.77M98.34165EAHECO Animal Health Group3.5604 of 5 starsGBX 73.25-0.3%GBX 150+104.8%-31.8%£49.63M£89.44M47.35234DNLDiurnal GroupN/AN/AN/AN/A£46.33M£4.68M-3.2133PXSProvexisN/AGBX 0.71-3.9%N/A+11.0%£16.57M£846.98K-26.774Gap DownMXCArgent BioPharmaN/AN/AN/AN/A£9.65M£1.32M-13.255Gap UpRGTArgent BioPharmaN/AN/AN/AN/A£8.31MN/A-0.65N/AGap DownHigh Trading Volume Related Companies and Tools Related Companies AMYT Competitors APH Competitors ANCR Competitors STX Competitors VLG Competitors EAH Competitors DNL Competitors PXS Competitors MXC Competitors RGT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:AGY) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Allergy Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access